One stock that might be an intriguing choice for investors right now is BioTime, Inc. BTX. This is because this security in the Medical-Biomedical/Genetics space is seeing solid earnings estimate ...

BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is ...

BioTime has appointed Brian Culley to serve as its sole CEO, as part of a corporate restructuring executed by the board of directors. Culley takes over for co-CEOs Adi Mohanty and Michael West, ...

BioTime, Inc. announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human Embryonic Stem (hES) cell lines available to California-based ...

BioTime, Inc.Peter Garcia, 510-521-3390, ext 367Chief Financial OfficerorJudith Segall, 510-521-3390, ext 301orLifeMap Sciences, Inc.Kenneth Elsner, 781-826-7719COO BioTime, Inc. (NYSE MKT: BTX) and ...

Resource is expected to help researchers select the most suitable progenitor cell lines. Regenerative medicines firm BioTime has teamed up with XenneX to establish LifeMap Sciences, an intiiative that ...

Geron's stem cell assets were given a new lease in early January when former CEO Tom Okarma, now heading a subsidiary of BioTime of Alameda, California, signed a definitive agreement for the latter to ...

Company will merge Xennex into LifeMap Sciences subsidiary. BioTime is to acquire Xennex to take over the latters’ global marketing rights to the GeneCards® and PanDaTox® databases. BioTime says it ...